ITCI News 16.15 Intra-Cellular Ther (ITCI)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intra-Cellular Ther (ITCI) 16.15 $ITCI

Intra-Cellular Therapies Announces Multiple Presentations on ITI-007 at the 4th Biennial Schizophrenia International Research Society (SIRS) Conference
GlobeNewswire - Mon Apr 07, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders has presented several posters and a talk at the 4th Biennial Schizophrenia International Research Society (SIRS) conference being held in Florence, Italy.

Intra-Cellular Therapies Announces Upcoming Presentations at the 4th Biennial Schizophrenia International Research Society Conference
GlobeNewswire - Wed Apr 02, 10:20AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that one oral presentation and four posters on ITI-007, the Company's lead drug candidate for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders, will be featured at the 4 Biennial Schizophrenia International Research Society (SIRS) Conference. The meeting will be held April 5-9, 2014, in Florence, Italy. The presentation and posters will feature data from ITI-007-005, the Company's recently completed Phase 2 clinical trial in patients with an acutely exacerbated episode of schizophrenia, as well as data on the metabolism, unique target profile, and mechanism of action of ITI-007.

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2013 Financial Results
GlobeNewswire - Tue Mar 25, 3:01PM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31, 2013, and provided an update on corporate developments and upcoming events.

Intra-Cellular Therapies to Announce 2013 Fourth Quarter And Full Year Financial Results and to Host Conference Call on Tuesday, March 25, at 4:30 pm Eastern Time
PR Newswire - Tue Mar 18, 3:00PM CDT
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and a live Internet webcast at 4:30 p.m. Eastern Time on Tuesday March 25, 2014 to discuss the financial results for the fourth quarter and year ended December 31, 2013.

Intra-Cellular Therapies hires Dr Juan Sanchez as VP of Corporate Communications and Investor Relations
M2 - Tue Mar 11, 5:59AM CDT
Biopharmaceutical company Intra-Cellular Therapies (NasdaqGS :ITCI) revealed on Monday the election of Juan Sanchez MD, as vice president of its Corporate Communications and Investor Relations.

Intra-Cellular Therapies Announces the Appointment of Juan Sanchez, M.D., as Vice President of Corporate Communications and Investor Relations
PR Newswire - Mon Mar 10, 6:30AM CDT
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of Juan Sanchez, M.D., as Vice President of Corporate Communications and Investor Relations. Dr. Sanchez will report to Sharon Mates, Ph.D., CEO and Chairman of Intra-Cellular Therapies.

Intra-Cellular Therapies Announces Initiation of Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients with Dementia, Including Alzheimer's Disease
PR Newswire - Mon Mar 03, 6:00AM CST
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease. The commencement of this study marks an important milestone in our strategy to develop low doses of ITI-007 for the treatment of behavioral disturbances associated with dementia and related disorders.

Intra-Cellular Therapies to Present at the Cowen and Company 34th Annual Healthcare Conference
PR Newswire - Wed Feb 26, 3:00PM CST
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced Dr. Sharon Mates, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 34th Annual Healthcare Conference on March 3, 2014 at 2:50 p.m. Eastern Time in Boston, MA. Dr. Mates will provide a corporate overview and business update.

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 14, 3:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/5m252n/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2013" report to their offering. 'Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS). Scope - A snapshot of the global therapeutic scenario for Cognitive Impairment Associated With Schizophrenia (CIAS). - A review of the Cognitive Impairment Associated With Schizophrenia (CIAS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cognitive Impairment Associated With Schizophrenia (CIAS) Overview Therapeutics Development Clinical Stage Products Early Stage Products Unknown Stage Products Drug Profiles AQW-051 - Drug Profile AVN-211 - Drug Profile eltoprazine - Drug Profile ABT-126 - Drug Profile erteberel - Drug Profile ITI-214 - Drug Profile SKL-15508 - Drug Profile AN-761 - Drug Profile Alpha-7 Program - Drug Profile SEN-15924 - Drug Profile PNU-120596 - Drug Profile A-582941 - Drug Profile A-431404 - Drug Profile MGluR5 PAM - Drug Profile CDD-0304 - Drug Profile NR-2B Positive Allosteric Modulators - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Appendix Companies Mentioned Eli Lilly and Company Avineuro Pharmaceuticals, Inc. Novartis AG Pfizer Inc. Mithridion, Inc. Upsher-Smith Laboratories, Inc. PsychoGenics, Inc. Siena Biotech S.p.A. Intra-Cellular Therapies, Inc. Mnemosyne Pharmaceuticals, Inc. SK Biopharmaceuticals Co., Ltd. Merz Pharmaceuticals GmbH AbbVie Inc. Aniona ApS For more information visit http://www.researchandmarkets.com/research/5m252n/cognitive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Intra-Cellular Therapies to Present at Two Upcoming Healthcare Conferences
PR Newswire - Fri Feb 07, 7:00AM CST
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced Dr. Sharon Mates, Ph.D., President and Chief Executive Officer, will present at the 16th Annual BIO CEO and Investor Conference on February 10, 2014 at 4:30 p.m. Eastern Time at the Waldorf Astoria New York. Dr. Mates is also scheduled to present in a fireside chat discussion at the 2014 Leerink Global Healthcare Conference on February 12th, 2014 at 08:50 a.m. Eastern Time also at the Waldorf Astoria New York.

Intra-Cellular Therapies Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
PR Newswire - Wed Feb 05, 12:04PM CST
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, today announced the completion of its previously announced underwritten public offering of 6,142,000 shares of its common stock at a public offering price of $17.50 per share. In addition, the underwriters have exercised in full their option to purchase an additional 921,300 shares of common stock at the public offering price.

Intra-Cellular Therapies Announces Pricing of Public Offering of Common Stock; To Begin Trading on NASDAQ Global Select Market under "ITCI"
PR Newswire - Thu Jan 30, 8:15PM CST
Intra-Cellular Therapies, Inc. (OTCQB: ITCI), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, today announced the pricing of an underwritten public offering of 6,142,000 shares of its common stock at a public offering price of $17.50 per share. In addition, Intra-Cellular has granted the underwriters a 30-day option to purchase up to an additional 921,300 shares of common stock. In connection with the offering, shares of Intra-Cellular common stock will commence trading on the NASDAQ Global Select Market tomorrow morning under the ticker "ITCI."

Intra-Cellular Therapies Cleared for Quotation on OTCQB
PR Newswire - Thu Dec 19, 6:25PM CST
Intra-Cellular Therapies, Inc. ("ITI" , a biopharmaceutical company focused on the development of therapeutics for CNS disorders, announced that its common stock has been approved for quotation on the OTC Markets - OTCQB tier (OTCQB) under the symbol "ITCI", and is expected to begin trading on December 20, 2013.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 94

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 96

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 142

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 154

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 141

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading
Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 133

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
Volta M100 Puts Flexibility at Pad Printing's Center

Updated Category News Views 55

A tabletop printer rarely earns a second glance, but the Volta M100 is making a sensible argument: small manufacturers do not need another rigid box that becomes obsolete the minute a job changes. Boston Industrial Solutions has introduced the Volta M100 as a pad-printing machine built around adjustability, operator convenience, and software that can be upgraded as...

Continue Reading
ArchiPro Enters U.S. Design Market With Curated Bet

Updated Category News Views 44

Blue-chip furniture and glossy project photos are not a moat by themselves, no matter how hard a platform tries to make them look like one. But ArchiPro’s full U.S. launch deserves a closer look because it arrives with something many would-be marketplace operators lack: more than a decade of operating history in New Zealand and Australia. A Three-Sided Machine Meets...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 25

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Cambrian Turns Dairy Wastewater Into Long-Term Gas

Updated Category News Views 65

A Wisconsin dairy plant just traded lagoon duty for a 20-year service arrangement, and that is more consequential than the usual shiny renewable-gas headline. Cambrian Innovation says it has commissioned and is operating a wastewater treatment and resource recovery system that handles roughly 280,000 gallons a day. That works out to about 102 million gallons annually, a...

Continue Reading

Top 5 Most Recently Viewed Articles

Rogers Communications Adjusts Revenue Forecast After Sports Deal

Updated Category News Views 203

Rogers Communications Expands Outlook Following Sports Acquisition Rogers Communications, Inc. (NYSE: RCI) has made headlines after raising its full-year service revenue guidance following a solid earnings performance. Despite a slight decline in stock value, investors reacted positively to the company's updated expectations after their second-quarter financial report....

Continue Reading
Tata Communications Expands AI Capabilities with New Acquisition

Updated Category News Views 188

Tata Communications Enhances AI Capabilities Tata Communications, a prominent player in the global communications technology landscape, has recently taken a significant step in advancing its AI capabilities. The company announced its acquisition of a 51% stake in Commotion Inc., an innovative AI-native Enterprise SaaS platform. This acquisition highlights Tata...

Continue Reading
Taboola to Announce Q3 2024 Earnings: Conference Call Details

Updated Category News Views 152

Taboola Prepares for Third Quarter 2024 Financial Announcement Taboola, renowned for its dynamic recommendation platform, is making headlines as it gears up to release its financial results for the third quarter of 2024. This exciting event is scheduled for a Thursday morning before the market opens, paving the way for insights into the company's performance. Date and...

Continue Reading
Aker Horizons ASA Holds Key Extraordinary General Meeting

Updated Category News Views 126

Aker Horizons ASA Holds Key Extraordinary General Meeting In a significant step for Aker Horizons ASA, the company's extraordinary general meeting was successfully conducted. The meeting, held digitally, emphasized the importance of engaging stakeholders through innovative online participation. This format makes it easier for shareholders to be involved, regardless of...

Continue Reading
Energizer® Portable Power Expands European Availability Now

Updated Category News Views 147

Energizer® Portable Power Expands European Availability Energizer, a name synonymous with reliable power solutions, has taken a bold step forward with the expansion of its portable power ecosystem across Europe. This strategic move by TennRich International Corp. signals a commitment to enhancing modern lifestyles, perfectly aligning with the needs of consumers at home,...

Continue Reading